Cepheid Nabs CE-IVD Mark for Molecular NPM1 Mutation Test for AML Monitoring
The test quantifies mutant NPM1 mRNA transcripts in peripheral blood specimens from patients with acute myeloid leukemia.
Bristol Myers Squibb Eyeing CLL, SLL as Additional Breyanzi Indications After Positive Readout
Around 18 percent of patients in a Phase I/II trial with aggressive, treatment-refractory forms of leukemia had complete responses on the CAR T-cell therapy.
Tibsovo added to a standard two-drug treatment regimen extended event-free survival and reduced treatment failure in patients with IDH1-mutant acute myeloid leukemia.
Mustang Bio Reprioritizes Pipeline, Sells Manufacturing Facility to Focus on Lead Assets
The company said it is nixing several pipeline programs and selling a manufacturing plant to uBriGene in order to focus on a CD20 CAR T-cell therapy and other nearer term opportunities.
Invivoscribe Leukemia CDx Assay Nabs IVDR Approval
The PCR-based test detects internal tandem duplications and tyrosine kinase domain mutations D835 and I836 in the FLT3 gene in patients with acute myelogenous leukemia.